Diversified Trust Co Has $276,000 Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Diversified Trust Co decreased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 65.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,880 shares of the biotechnology company’s stock after selling 9,417 shares during the period. Diversified Trust Co’s holdings in BioMarin Pharmaceutical were worth $276,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMRN. Activest Wealth Management acquired a new position in shares of BioMarin Pharmaceutical in the 4th quarter valued at $26,000. CIBC Private Wealth Group LLC grew its holdings in BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 179 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in BioMarin Pharmaceutical during the third quarter valued at approximately $40,000. Parallel Advisors LLC increased its stake in BioMarin Pharmaceutical by 62.2% in the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 295 shares in the last quarter. Finally, V Square Quantitative Management LLC bought a new stake in BioMarin Pharmaceutical in the fourth quarter valued at approximately $45,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Gregory R. Friberg sold 3,281 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $53.85, for a total transaction of $176,681.85. Following the sale, the executive vice president owned 51,818 shares in the company, valued at $2,790,399.30. This represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

NASDAQ BMRN opened at $59.00 on Friday. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $11.40 billion, a price-to-earnings ratio of 43.06, a P/E/G ratio of 0.44 and a beta of 0.25. The firm’s 50 day simple moving average is $54.43 and its 200 day simple moving average is $56.51. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $66.28.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BMRN. Barclays lifted their price target on shares of BioMarin Pharmaceutical from $80.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 3rd. Royal Bank Of Canada restated a “sector perform” rating and issued a $66.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, May 5th. HC Wainwright reaffirmed a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Monday. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Weiss Ratings downgraded BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 11th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $88.67.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.